Welcome to Chinese Journal of Evidence-Based Pediatrics,Today is
中文版

Chinese Journal of Evidence-Based Pediatrics ›› 2022, Vol. 17 ›› Issue (6): 426-431.DOI: 10.3969/j.issn.1673-5501.2022.06.004

Previous Articles     Next Articles

Clinical features and prognosis in adolescents with malignant solid tumors in Beijing: A multicenter cross-sectional survey

SU Yan1a,8, HUANG Zhen2,8, LU Zheng3,8, LI Miao4,8, ZHI Tian5,8, SUN Qing6,8, ZHANG Zhaoxia7,8, WANG Huanmin1b, GE Ming1c, YU Tong1d, HE Lejian1e, LIU Rong7, ZHAO Weihong6, HUANG Dongsheng5, WU Wanshui4, GONG Jian3, NIU Xiaohui2, MA Xiaoli1a   

  1. 1 Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China, a. Pediatric Oncology Center, Medical Oncology Department, b. Department of Surgical Oncology, c. Department of Neurosurgery, d. Imaging Center, e. Department of Pathology; 2 Department of Orthopedic Oncology, Beijing Jishuitan Hospital, Capital Medical University, Beijing 100035, China; 3 Department of Pediatric Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; 4 Department of Pediatrics, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China; 5 Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China;6 Department of Pediatrics, Peking University First Hospital, Beijing 100034, China; 7 Department of Hematology, Children's Hospital, Capital Institute of Pediatrics, Beijing 100020, China; 8 Co-first author
  • Received:2022-05-20 Revised:2022-11-09 Online:2022-12-25 Published:2022-12-25
  • Contact: SU Yan; NIU Xiaohui; GONG Jian; WU Wanshui; HUANG Dongsheng; ZHAO Weihong; LIU Rong

PDF

136

Abstract: children and adults. Objective：To summarize the clinical characteristics and prognosis of adolescent malignant solid tumors in multiple centers in Beijing. Design：Cross-sectional survey. Methods：This retrospective study analyzed the clinical characteristics and prognosis of adolescents over the age of 120 months with the initial diagnosis of malignant solid tumors in seven hospitals in Beijing from January 1, 2010 to December 31, 2019. Main outcome measures：Three-year event free survival (EFS) and overall survival (OS). Results：A total of 411 patients were enrolled in this study with a median age of 150 months (120-216 months). In total, 239 patients(58.2%) were males and 172(41.8%) were females. There were 183 patients(44.5%) with central nervous system tumors, 82(20%) with Ewing sarcoma, 47(11.4%) with rhabdomyosarcoma, 33(8%) with neuroblastoma, 29(7.1%) with non-rhabdomyosarcoma soft tissue sarcomas, 18(4.4%) with extracranial germ cell tumors and 19(4.6%) with other rare tumors. Among the 411 patients, the top three regions of registered residence were North China(160 cases, 38.9%), East China(97 cases, 23.6%) , South Central China(70 cases, 17%). There were 129 patients(31.4%) treated at one hospital, 180 patients(43.8%) at two hospitals, and 102 patients (24.8%) at three or more hospitals. The median follow-up time of 411 patients was 26 months(1-120 months). At the end of follow-up, 333 patients (81.0%) survived, 78 patients(19%) died, and 145 patients(35.3%) had tumor relapse or progression. The 3-year EFS rate was 60.3%, and the 3-year OS rate was 79.5%. The median survival time of 78 cases of death was 13 months(1-65 months), including 22 patients(28.2%) with central nervous system tumors, 18(23.1%) with rhabdomyosarcoma, 16(20.5%) with Ewing sarcoma, 8(10.3%) with neuroblastoma, 3(3.8%) with extracranial malignant germ cell tumors, 5(6.4%) with non-rhabdomyomatous soft tissue sarcomas and 6(7.7%) with rare tumors. Conclusion：Center nervous system tumors are the most common malignant solid tumors in adolescents. The prognosis of neuroblastoma, rhabdomyosarcoma and extracranial malignant germ cell tumor in adolescents is poor.

Key words: Adolescents, Solid tumors, Prognosis, Multicenter